Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial

Bibliographic Details
Title:	Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial
Authors:	Esrick, Erica B., Federico, Amy ^, Abriss, Daniela ^, Armant, Myriam ^, Boardman, Kari ^, Brendel, Christian ^, Ciuculescu, Marioara-Felicia ^, Daley, Heather ^, Dansereau, Colleen ^, Fernandes, Augustine ^, Heeney, Matthew M., Justus, David G. ^, Kao, Pei-Chi ^, Kim, Annette S., Kohn, Donald B., Lehmann, Leslie E., Liu, Donghui ^, London, Wendy B., Manis, John P, Moore, Theodore B., Morris, Emily ^, Pellin, Danilo ^, Proeung, Ellen ^, Richard, Shanna ^, Roach, Gavin D., Shaw, Kit L. ^, Terrazas, Dayna ^, White, Shanna L ^*, Williams, David A.
Source:	In Blood 15 November 2022 140 Supplement 1:10665-10667
Database:	ScienceDirect